Compare BIO-TECHNE Corp (TECH) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Target Corporation — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Target Corporation trades at $152.3 (market cap $69.05B). The key difference: Target Corporation is far larger — about 6.1× BIO-TECHNE Corp's market cap, and Target Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| TECH | TGT | |
|---|---|---|
Market Cap | $11.24B | $69.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $152.09 |
52-Week Low | $43.31 | $83.68 |
Enterprise Value | $11.32B | $84.34B |
Dividend Yield | 0.44% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Target (TGT) trades at $149.70, up 1.77% today and near its 52-week high of $151.23, with a bullish technical trend and strong recent earnings beats. The stock shows solid fundamentals with a P/E of 19.78 and net income margin of 3.24%, supported by positive cash flow trends. Recent analyst upgrades and media coverage highlight optimism around the retailer's turnaround and upcoming Q2 results.
The outlook for TGT is positive, driven by consistent earnings outperformance and improving cash flow, though risks include competitive retail pressures and potential margin compression. With a consensus price target of $146.19 and bullish analyst sentiment, the stock offers upside potential, but investors should monitor consumer spending trends and quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
